Biomek NGeniuS System from Beckman coulter life sciences
Beckman Coulter Life Sciences, a worldwide chief in laboratory automation and innovation, in partnership with Illumina, a frontrunner in DNA sequencing and array-based applied sciences, provides a promising new strategy to oncology analysis delivering quicker outcomes with fewer touchpoints. The Illumina TruSight™ Oncology 500 DNA/RNA assay on the Biomek NGeniuS System from Beckman Coulter Life Sciences offers an revolutionary automated resolution enabling complete genomic profiling of tumor samples.
The applying helps each DNA and RNA inputs, enabling the detection of vital most cancers biomarkers together with single nucleotide variants (SNVs), insertions, deletions, gene amplifications, fusions, and splice occasions. Full library preparation may be achieved in lower than three days, offering quicker outcomes with automated precision from pattern preparation to sequencing.
4 to 24 libraries may be processed in a single batch, accommodating each high-quality and low-quality FFPE samples. The assay can be optimized for diminished plastic use and decrease consumable prices, making cutting-edge analysis extra accessible and sustainable.
“Delivering vital analysis outcomes quicker is paramount in all that we do in subsequent technology sequencing and past,” stated Ewan Grant, Senior Director of the Biotech Workflow Options Enterprise Unit at Beckman Coulter Life Sciences. “The continued collaboration with Illumina goals to speed up the journey from pattern to perception, and the launch of this new software demonstrates our dedication to allow our prospects to ship knowledge faster and extra reliably with out the difficulties of guide workflows.”
The brand new software joins the Illumina DNA Prep, DNA PCR-Free Prep, and RNA Prep with Enrichment functions, that are all accessible in a first-of-its-kind open chemistry, cloud-based Biomek NGeniuS System Purposes Library.
“We’re happy to proceed our collaboration with Beckman Coulter Life Sciences by means of the event of the Illumina DNA PCR Free and Illumina TruSight Oncology 500 DNA technique to be used on the Biomek NGeniuS liquid dealing with system to allow NGS-based oncology testing,” stated Mike Kreitzinger, Senior Director, Scientific Technique & Partnership, Americas at Illumina. “For our mutual prospects, the event of automated strategies on the Biomek NGeniuS System will considerably scale back hands-on time, enhance buyer expertise, and proceed to allow genomics as a vital software for medical analysis in oncology.”
Launched in June of 2022, the Biomek NGeniuS System is a purpose-built liquid handler for low-medium throughput subsequent technology sequencing (NGS) library preparation. It offers an easy-to-use automation resolution that reduces user-errors, guide transfers, and hands-on time for the historically labor-intensive strategy of NGS library building.
The Illumina TruSight Oncology 500 DNA/RNA pattern preparation technique and extra functions centered round most cancers analysis, infectious illness analysis, and focused sequencing is the most recent installment in a sequence of automation software collaborations between the 2 corporations introduced in February 2022.
